Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Vaseem Mahboob Sells 4,788 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 4,788 shares of the business’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $30.60, for a total value of $146,512.80. Following the completion of the sale, the chief financial officer owned 60,609 shares of the company’s stock, valued at $1,854,635.40. This trade represents a 7.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, October 27th, Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.04, for a total transaction of $1,045,662.36.
• On Wednesday, October 28th, Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.48, for a total transaction of $1,216,243.44.
• On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.88, for a total transaction of $680,307.56.
• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total transaction of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.

Kestra Medical Technologies Trading Down 3.0%

Shares of NASDAQ KMTS opened at $29.69 on Friday. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -11.12 and a beta of 0.51. Kestra Medical Technologies, Ltd. has a 12-month low of $17.34 and a 12-month high of $31.06. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock’s 50 day simple moving average is $26.69 and its 200 day simple moving average is $23.82.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The company had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. Equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC raised its position in shares of Kestra Medical Technologies by 834.0% during the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock worth $25,000 after buying an additional 784 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after acquiring an additional 5,731 shares during the period. California State Teachers Retirement System lifted its stake in shares of Kestra Medical Technologies by 39.2% in the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after acquiring an additional 7,844 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kestra Medical Technologies during the third quarter valued at approximately $353,000. Finally, Quantinno Capital Management LP acquired a new position in shares of Kestra Medical Technologies during the first quarter valued at approximately $431,000.

Analysts Set New Price Targets

KMTS has been the subject of a number of analyst reports. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Evercore assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Oppenheimer assumed coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.00.

Key Headlines Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.